Kevin Stankiewicz
CNBC
New York, NY, United States
Contact Kevin
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Kevin:
Oracle buddies up with Microsoft. Plus our take on Salesforce and Meta news
Microsoft (MSFT) and Oracle (ORCL) announce a product with the potential to benefit both stocks. Also: Salesforce is hiring, and Meta denies a WhatsApp report. → Read More
Oil prices are at 10-month highs. Here's what Cramer thinks it means for two energy stocks
West Texas Intermediate crude, the U.S. oil benchmark, has jumped 32% since its lows of the summer, to nearly $89 a barrel. → Read More
Jim Cramer says 'watch Ford as a barometer' of potential United Auto Workers strike risk
Ford Motor's (F) stock may offer clues into Wall Street's current attitude toward potential strikes by the United Auto Workers union, CNBC's Jim Cramer said. → Read More
Jim Cramer sees 'green shoot' in stock market reaction to this secondary stock sale
The market reaction to a $300 million secondary stock offering from Dutch Bros (BROS) is an encouraging sign, CNBC's Jim Cramer said. → Read More
This health-care stock is set to complete another spin-off. Here's what it means for our position in the stock
Medical equipment giant Danaher (DHR) will officially separate from its environmental-and-applied solutions segment later this month. → Read More
The huge rally in Salesforce's stock isn't over: Here's how high we see it going
"Even as the stock has rallied, it deserves to go much higher," says Jim Cramer. → Read More
AI in focus: Here's what to look for when Salesforce and Broadcom report earnings
When these two tech firms release earnings, Wall Street will be looking to see if their respective bets on artificial intelligence are starting to pay off. → Read More
Jim Cramer says this surging cybersecurity is gaining market share and proving doubters wrong
Palo Alto Networks is a compelling stock to own as it gains share in the increasingly important cybersecurity market, CNBC's Jim Cramer said. → Read More
Salesforce raises prices for the first time in 7 years. What it means for the stock
Indeed, Tuesday's news underscores co-founder and CEO Marc Benioff's commitment to growing profits at Salesforce. → Read More
We know A.I. is big for Nvidia. But new estimates of just how big are staggering
Goldman Sachs put out its medium-term estimate of Nvidia's generative artificial intelligence opportunity. → Read More
Two health-care stocks are in the headlines. How the news impacts our investments
Positive developments for one of Eli Lilly's (LLY) rivals in Alzheimer's treatments are good news for the Club holding. But, Humana catches a downgrade. → Read More
History shows Wall Street can sustain its first half advance. How Jim Cramer is playing it
The stock market's strong first-half performance may be a tough act to follow. → Read More
Here are our 4 best stocks — and 4 worst stocks — of the first half of 2023
Tech stocks were the standout performers in the first half of 2023, powering Wall Street — and the Club's portfolio. → Read More
Apple's all-time high is not the only one in our portfolio. Plus, why Nvidia is rebounding
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET. → Read More
Wall Street shows ongoing frustration with an entertainment giant, sees gains ahead for 2 retailers
Wall Street showed ongoing — and understandable — frustration with Walt Disney's (DIS) lackluster share-price performance. → Read More
Nvidia knocks down concern over AI chip exports to China. The reason is why we own the stock
Nvidia (NVDA) on Wednesday reassured investors that potential export restrictions on chips wouldn't hurt the semiconductor firm's bottom line. → Read More
Here's a list of weight-loss drugs in development and awaiting approval to take on Ozempic
After a busy few days for the diabetes-and-obesity drug industry, our conviction in Eli Lilly (LLY) remains intact. → Read More
New data fortifies Eli Lilly's standing in the burgeoning market for weight-loss drugs
The drugmaker's oral obesity pill demonstrated impressive efficacy in a mid-stage study. → Read More
Be patient with this red-hot tech stock, as it soars to new all-time high
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET. → Read More
Stocks fall, but Jim Cramer says its not time to buy yet
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET. → Read More